

Scientific and Industrial Research, New Delhi (India) in the form of research grant (Scheme No: 37(1395)/10/EMR-II) is gratefully acknowledged.

REFERENCES

- Baggot J D. 1977. Principles of pharmacokinetics. *Principles of Drug Disposition in Domestic Animals*. pp. 144–89. WB Saunders Co. Philadelphia.
- Craig W A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clinical Infectious Diseases* **26**: 1–10.
- Gibaldi M and Perrier D. 1982. *Pharmacokinetics*. Marcell Dekker Inc., New York.
- Lode H, Borner K and Koeppe P. 1998. Pharmacodynamics of fluoroquinolones. *Clinical Infectious Diseases* **27**: 33–39.
- Lou S, Li W and Hu Q. 2007. Influence of cefoperazone and azithromycin on the pharmacokinetics of pazufloxacin in rats. *European Journal of Drug Metabolism and Pharmacokinetics* **32**(4): 219–23.
- Mitsuyama J, Takahata M, Yamashiro Y, Kitayama R, Muratani T, Matsumura N, Nakata M, Fukuta T, Yamada H, Maehana J, Hamada S, Sugiyama H, Shimakura M, Minami S, Watanabe Y and Narita H. 1999. Antibacterial activity of a new injectable quinolone, pazufloxacin mesilate (PZFX mesilate), *in vitro* and *in vivo*. *Japanese Journal of Chemotherapy* **47**: 37–64.
- Nakata M, Yamashiro Y, Shimakura M, Takahata M, Minami S, Watanabe Y and Narita H. 1999. Pharmacokinetics of pazufloxacin mesilate in experimental animals. *Japanese Journal of Chemotherapy* **47**: 65–75.
- Nomura N, Mitsuyama J, Furuta Y, Yamada H, Nakata M, Fukuda T, Yamada H, Takahata M and Minami S. 2002. *In vitro* and *in vivo* antibacterial activities of pazufloxacin mesilate, a new injectable quinolone. *The Japanese Journal of Antibiotic* **55**(4): 412–39.
- Pathania R and Sharma S K. 2010. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. *Research in Veterinary Science* **89**(1): 108–12.
- Phapale P B, Lee H W, Kim S, Lim M, Kale D D, Lee J M, Park J H, Moon S and Yoon Y. 2010. Analysis of pazufloxacin mesilate in human plasma and urine by LC with fluorescence and UV detection and its application to pharmacokinetic study. *Chromatographia* **71**: 101–06.
- Raipuria M, Dumka V K and Sandhu H S. 2007. Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves. *Veterinary Research Communications* **31**: 1013–20.
- Sappal R, Chaudhary R K, Sandhu H S and Sidhu P K. 2009. Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (*Bubalus bubalis*). *Veterinary Research Communications* **33**: 659–67.
- Sharma S K, Aditi and Shah Ahsan Ul Haq. 2014. Influence of *Escherichia coli* lipopolysaccharide induced fever on the plasma kinetics of pazufloxacin in buffalo calves. *Indian Journal of Animal Sciences* **84**(2): 166–69.
- Shojaee Aliabadi F and Lees P. 2000. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation. *International Journal of Antimicrobial Agents* **14**: 307–13.
- Toutain P L and Bousquet-Melou A. 2004. Volumes of distribution. *Journal of Veterinary Pharmacology and Therapeutics* **27**: 441–53.
- Toutain P L and Lees P. 2004. Integration and modeling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. *Journal of Veterinary Pharmacology and Therapeutics* **27**: 467–77.
- Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. *Drugs* **58**: 29–36.
- Walker R D. 2000. Fluoroquinolones. *Antimicrobial Therapy in Veterinary Medicine*. 3rd edn, pp. 315–38. (Eds) Prescott J F, Baggot D and Walker R D. Iowa State University Press, Ames, USA.
- Zhanel G G, Ennis K, Vercaigne L, Walkty A, Gin A S, Embil J, Smith H and Hoban D J. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. *Drugs* **62**: 13–59.
- Zhanel G G, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin A M, Gin A S, Rubinstein E and Hoban D J. 2006. A review of new fluoroquinolones: focus on their use in respiratory tract infections. *Treatment in Respiratory Medicine* **5**: 437–65.